ArticleEuropean journal of nuclear medicine and molecular imaging2012
Predictive value of pretreatment metabolic activity measured by fluorodeoxyglucose positron emission tomography in patients with metastatic advanced gastric cancer: the maximal SUV of the stomach is a prognostic factor.
Article in European journal of nuclear medicine and molecular imaging, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Prognostic value of pretreatment standardized uptake value of F-18-fluorodeoxyglucose PET in patients with gastric cancer: a meta-analysis.BMC cancer · 2017Pooled it
- Subcutaneous adipose tissue [European journal of nuclear medicine and molecular imaging · 2025Article
- Predictive Value of Preoperative Maximum Standardized Uptake Value (SUVmax) in Patients with Advanced Gastric Cancer.Biomedicines · 2025Article
- Prognostic value of the metabolic score obtained via [Scientific reports · 2022Article
- Low metabolic activity in primary gastric adenocarcinoma is associated with resistance to chemoradiation and the presence of signet ring cells.Surgery today · 2020Article
- Prognostic Value of Restaging F-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography to Predict 3-Year Post-Recurrence Survival in Patients with Recurrent Gastric Cancer after Curative Resection.Korean journal of radiology · 2020Article
- Prognostic Value of Metabolic Information in Advanced Gastric Cancer Using PreoperativeNuclear medicine and molecular imaging · 2019Article
- AChinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2019Article
- PET/CT in thyroid nodule and differentiated thyroid cancer patients. The evidence-based state of the art.Reviews in endocrine & metabolic disorders · 2019Review
- The prognostic value of volume-based parameters usingGastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2018Article
- Potential Utility of FDG PET-CT as a Non-invasive Tool for Monitoring Local Immune Responses.Journal of gastric cancer · 2017Article
- Article
- Article
- Correlation of Primary Tumor FDG Uptake with Histopathologic Features of Advanced Gastric Cancer.Nuclear medicine and molecular imaging · 2015Article
- Prognostic value and clinical correlations of 18-fluorodeoxyglucose metabolism quantifiers in gastric cancer.World journal of gastroenterology · 2015Article
- ¹⁸F-FDG uptake as a prognostic variable in primary differentiated thyroid cancer incidentally detected by PET/CT: a multicentre study.European journal of nuclear medicine and molecular imaging · 2014Article
- Pretreatment F-18 FDG PET/CT Parameters to Evaluate Progression-Free Survival in Gastric Cancer.Nuclear medicine and molecular imaging · 2014Article
- Imaging of Gastric Cancer Metabolism Using 18 F-FDG PET/CT.Journal of gastric cancer · 2014Review
- Appropriateness criteria of FDG PET/CT in oncology.The Indian journal of radiology & imagingArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeFew studies have evaluated metabolic activity by (18)F-FDG PET as a prognostic factor in advanced gastric cancer (AGC). We investigated its prognostic role in metastatic AGC.
methodsWe enrolled 82 patients with metastatic AGC, who were treatment-naive and underwent pretreatment (18)F-FDG PET/CT scanning. In each patient, the maximal standardized uptake value (SUVmax) was measured in each target lesion. Stomach(SUVmax) was defined as SUVmax in the stomach, while Total(SUVmax) was defined as the highest SUVmax among all the target lesions.
resultsThe stomach was the organ most frequently displaying the highest SUVmax among all the target lesions (in 67.1% of patients). A Total(SUVmax) value of 11.5 was the value with the maximum sum of sensitivity and specificity from receiver-operating characteristic curves for progression-free survival (PFS). PFS was significantly longer in patients with a Total(SUVmax) value <11.5 than in those with a Total(SUVmax) value ≥11.5 (P = 0.023); however, overall survival (OS) was not (P = 0.055). A Stomach(SUVmax) value of 6.0 was derived by similar methods. PFS and OS were significantly longer in those with a Stomach(SUVmax) value <6.0 than in those with a Stomach(SUVmax) value ≥6.0 (P = 0.001 and P = 0.006, respectively). Furthermore, those with a low Total(SUVmax) and those with a low Stomach(SUVmax) showed better chemotherapeutic responses (P = 0.016 and P = 0.034, respectively). Among patients with histologically undifferentiated carcinomas, those with lower Total(SUVmax) and those with lower Stomach(SUVmax) showed longer median PFS (P = 0.027 and P = 0.005, respectively) and OS (P = 0.009 and P <0.001, respectively). Multivariate analysis demonstrated Stomach(SUVmax) as an independent predictor of PFS (P = 0.002) and OS (P = 0.038).
conclusionPretreatment metabolic activity may be a useful prognostic marker in patients with metastatic AGC undergoing palliative chemotherapy. Notably, Stomach(SUVmax) was the single, most robust factor predicting prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.